External beam radiotherapy synergizes ¹⁸⁸Re-liposome against human esophageal cancer xenograft and modulates ¹⁸⁸Re-liposome pharmacokinetics

References

• JemalASiegelRWardEHaoYXuJThunMJCancer statistics, 2009CA Cancer J Clin200959422524919474385
   PubMed Web of Science ®Google Scholar
• CooperJSGuoMDHerskovicAChemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology GroupJAMA1999281171623162710235156
   PubMed Web of Science ®Google Scholar
• TepperJKrasnaMJNiedzwieckiDPhase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781J Clin Oncol20082671086109218309943
   PubMed Web of Science ®Google Scholar
• LiuHCHungSKHuangCJEsophagectomy for locally advanced esophageal cancer, followed by chemoradiotherapy and adjuvant chemotherapyWorld J Gastroenterol200511345367537216149148
   PubMedGoogle Scholar
• Chiarion-SileniVCortiLRuolAPhase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancerBr J Cancer200796343243817245338
   PubMedGoogle Scholar
• WahbaHAEl-HadaadHAAbd-EllatifEANeoadjuvant concurrent chemoradiotherapy with capecitabine and oxaliplatin in patients with locally advanced esophegeal cancerMed Oncol20122931693169821706368
   PubMed Web of Science ®Google Scholar
• KooDHParkSIKimYHPhase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up dataCancer Chemother Pharmacol201269365566321968953
   PubMedGoogle Scholar
• SwisherSGHofstetterWWuTTProposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT)Ann Surg20052415810817 discussion 817–82015849517
   PubMed Web of Science ®Google Scholar
• DashAKnappFFPillaiMRTargeted radionuclide therapy – an overviewCurr Radiopharm20136315218024059327
   PubMedGoogle Scholar
• MitraANanALineBRGhandehariHNanocarriers for nuclear imaging and radiotherapy of cancerCurr Pharm Des200612364729474917168775
   PubMed Web of Science ®Google Scholar
• HafeliUTiefenauerLXSchbigerPAWederHGA lipophilic complex with 186Re/188Re incorporated in liposomes suitable for radiotherapyInt J Rad Appl Instrum B19911854494541670497
   PubMedGoogle Scholar
• BaoAGoinsBKlipperRNegreteGPhillipsWT186Re-liposome labeling using 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in ratsJ Nucl Med200344121992199914660726
   PubMedGoogle Scholar
• ChenLCChangCHYuCYBiodistribution, pharmacokinetics and imaging of (188)Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse modelNucl Med Biol200734441542317499731
   PubMedGoogle Scholar
• ChangYJChangCHChangTJBiodistribution, pharmacokinetics and microSPECT/CT imaging of 188Re-bMEDA-liposome in a C26 murine colon carcinoma solid tumor animal modelAnticancer Res2007274B2217222517695506
   PubMed Web of Science ®Google Scholar
• WangSXBaoAHerreraSJIntraoperative 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin modelClin Cancer Res200814123975398318559620
   PubMedGoogle Scholar
• ChangYJChangCHYuCYTherapeutic efficacy and micro SPECT/CT imaging of 188Re-DXR-liposome in a C26 murine colon carcinoma solid tumor modelNucl Med Biol20103719510420122674
   PubMedGoogle Scholar
• ChenMHChangCHChangYJMicroSPECT/CT imaging and pharmacokinetics of 188Re-(DXR)-liposome in human colorectal adenocarcinoma-bearing miceAnticancer Res2010301657220150618
   PubMed Web of Science ®Google Scholar
• ChangYJHsuCWChangCHLanKLTingGLeeTWTherapeutic efficacy of 188Re-liposome in a C26 murine colon carcinoma solid tumor modelInvest New Drugs201331480181123224353
   PubMed Web of Science ®Google Scholar
• ChenLCChangCHYuCYPharmacokinetics, micro-SPECT/CT imaging and therapeutic efficacy of (188)Re-DXR-liposome in C26 colon carcinoma ascites mice modelNucl Med Biol200835888389319026950
   PubMed Web of Science ®Google Scholar
• ChenLCWuYHLiuIHPharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice modelNucl Med Biol2012391354321958858
   PubMedGoogle Scholar
• HsuCWChangYJChangCHComparative therapeutic efficacy of rhenium-188 radiolabeled-liposome and 5-fluorouracil in LS-174T human colon carcinoma solid tumor xenograftsCancer Biother Radiopharm201227848148923067100
   PubMed Web of Science ®Google Scholar
• TsaiCCChangCHChenLCBiodistribution and pharmacokinetics of 188Re-liposomes and their comparative therapeutic efficacy with 5-fluorouracil in C26 colonic peritoneal carcinomatosis miceInt J Nanomedicine201162607261922114492
   PubMed Web of Science ®Google Scholar
• TsengYLHongRLTaoMHChangFHSterically stabilized anti-idiotype immunoliposomes improve the therapeutic efficacy of doxorubicin in a murine B-cell lymphoma modelInt J Cancer199980572373010048974
   PubMed Web of Science ®Google Scholar
• MazumdarMSmithASchwartzLHA statistical simulation study finds discordance between WHO criteria and RECIST guidelineJ Clin Epidemiol200457435836515135836
   PubMed Web of Science ®Google Scholar
• HerskovicAMartzKal-SarrafMCombined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagusN Engl J Med199232624159315981584260
   PubMed Web of Science ®Google Scholar
• van HagenPHulshofMCvan LanschotJJPreoperative chemoradiotherapy for esophageal or junctional cancerN Engl J Med2012366222074208422646630
   PubMed Web of Science ®Google Scholar
• BassGAFurlongHO’SullivanKEHennessyTPWalshTNChemoradiotherapy, with adjuvant surgery for local control, confers a durable survival advantage in adenocarcinoma and squamous cell carcinoma of the oesophagusEur J Cancer20145061065107524480403
   PubMedGoogle Scholar
• MinskyBDPajakTFGinsbergRJINT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapyJ Clin Oncol20022051167117411870157
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRDrug delivery systems: entering the mainstreamScience200430356651818182215031496
   PubMed Web of Science ®Google Scholar
• LammersTHenninkWEStormGTumour-targeted nanomedicines: principles and practiceBr J Cancer200899339239718648371
   PubMed Web of Science ®Google Scholar
• SunQRadoszMShenYChallenges in design of translational nanocarriersJ Control Release2012164215616922664472
   PubMed Web of Science ®Google Scholar
• Oude BlenkeEMastrobattistaESchiffelersRMStrategies for triggered drug release from tumor targeted liposomesExpert Opin Drug Deliv201310101399141023796390
   PubMed Web of Science ®Google Scholar
• GreishKEnhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targetingMethods Mol Biol2010624253720217587
   PubMedGoogle Scholar
• MacPhersonKHCarrPDVergerDKwokTDavidsonBEOllisDLCrystallization of the N-terminal domain of the Escherichia coli regulatory protein TyrRActa Crystallogr D Biol Crystallogr199955Pt 111923192410531496
   PubMedGoogle Scholar
• TorchilinVPRecent advances with liposomes as pharmaceutical carriersNat Rev Drug Discov20054214516015688077
   PubMed Web of Science ®Google Scholar
• GoinsBAPhillipsWTNanoimaging Pan Stanford Series on Biomedical NanotechnologyLondon, EnglandCRC Press2011
   Google Scholar